Positive Results Observed in Family Caregivers of Patients with Lung Cancer After Interventions
the Cancer Therapy Advisor take:
Family caregivers (FCGs) who received an interdisciplinary palliative care intervention reported greater social well-being and less psychological distress and caregiver burden compared to those in the usual care cohort, according to an article published online in the journal Cancer.
Patients diagnosed with stage 1 through 4 non-small cell lung cancer identified primary FCGs who then took part in this study. Two groups were identified: the usual care group and the intervention cohort.
FCGs in the palliative care intervention group were presented at interdisciplinary care meetings and attended four educational sessions of physical, psychological, social, and spiritual domains. In the sessions, FCGs were supported through self-care plans.
At the beginning of the study and again 12 weeks later, FCGs were evaluated regarding caregiver burden, caregiving skills preparedness, psychological distress, and quality of life.
After 12 weeks in the palliative care intervention group, FCGs had increased scores of social well-being (5.84 vs. 6.86; P<0.001) and reduced scores of psychological distress (4.61 vs. 4.20; P=0.010), compared to those in the usual care group.
Results also showed that FCGs of patients with lung cancer in the interdisciplinary intervention group experienced significantly less caregiver burden than FCGs in the usual care cohort (P=0.008).
Family caregivers who received interdisciplinary palliative care intervention reported greater social well-being and less psychological distress.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM